These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 25903661)

  • 1. Impact of increasing adherence to disease-modifying therapies on healthcare resource utilization and direct medical and indirect work loss costs for patients with multiple sclerosis.
    Yermakov S; Davis M; Calnan M; Fay M; Cox-Buckley B; Sarda S; Duh MS; Iyer R
    J Med Econ; 2015; 18(9):711-20. PubMed ID: 25903661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medication adherence with disease modifying treatments for multiple sclerosis among US employees.
    Kleinman NL; Beren IA; Rajagopalan K; Brook RA
    J Med Econ; 2010; 13(4):633-40. PubMed ID: 20958113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis.
    Bergvall N; Petrilla AA; Karkare SU; Lahoz R; Agashivala N; Pradhan A; Capkun G; Makin C; McGuiness CB; Korn JR
    J Med Econ; 2014 Oct; 17(10):696-707. PubMed ID: 25019581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of persistence with therapy on inpatient admissions and emergency room visits in the US among patients with multiple sclerosis.
    Thomas NP; Curkendall S; Farr AM; Yu E; Hurley D
    J Med Econ; 2016; 19(5):497-505. PubMed ID: 26706292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US.
    Ivanova JI; Bergman RE; Birnbaum HG; Phillips AL; Stewart M; Meletiche DM
    J Med Econ; 2012; 15(3):601-9. PubMed ID: 22376190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Healthcare resource utilization following switch or discontinuation in multiple sclerosis patients on disease modifying drugs.
    Reynolds MW; Stephen R; Seaman C; Rajagopalan K
    J Med Econ; 2010 Mar; 13(1):90-8. PubMed ID: 20078189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct and indirect healthcare resource utilization and costs associated with ulcerative colitis in a privately-insured employed population in the US.
    Cohen R; Skup M; Ozbay AB; Rizzo J; Yang M; Diener M; Chao J
    J Med Econ; 2015 Jun; 18(6):447-56. PubMed ID: 25728698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health Care Resource Utilization and Costs in Patients with Chronic Myeloid Leukemia with Better Adherence to Tyrosine Kinase Inhibitors and Increased Molecular Monitoring Frequency.
    Latremouille-Viau D; Guerin A; Gagnon-Sanschagrin P; Dea K; Cohen BG; Joseph GJ
    J Manag Care Spec Pharm; 2017 Feb; 23(2):214-224. PubMed ID: 28125373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implications of real-world adherence on cost-effectiveness analysis in multiple sclerosis.
    Brandes DW; Raimundo K; Agashivala N; Kim E
    J Med Econ; 2013; 16(4):547-51. PubMed ID: 23391123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis.
    Burks J; Marshall TS; Ye X
    Clinicoecon Outcomes Res; 2017; 9():251-260. PubMed ID: 28496344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic impact of multiple sclerosis disease-modifying drugs in an employed population: direct and indirect costs.
    Birnbaum HG; Ivanova JI; Samuels S; Davis M; Cremieux PY; Phillips AL; Meletiche D
    Curr Med Res Opin; 2009 Apr; 25(4):869-77. PubMed ID: 19232041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct and Indirect Healthcare Resource Utilization and Costs Among Migraine Patients in the United States.
    Bonafede M; Sapra S; Shah N; Tepper S; Cappell K; Desai P
    Headache; 2018 May; 58(5):700-714. PubMed ID: 29446063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Healthcare resource utilization and costs in working-age patients with high-risk atherosclerotic cardiovascular disease: findings from a multi-employer claims database.
    Zhao Z; Zhu Y; Fang Y; Ye W; McCollam P
    J Med Econ; 2015; 18(9):655-65. PubMed ID: 25891183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of adherence to disease modifying therapies on long-term clinical and economic outcomes in multiple sclerosis: A claims analysis of real-world data.
    Amezcua L; Livingston T; Hayward B; Zhou J; Williams MJ
    Mult Scler Relat Disord; 2023 Sep; 77():104866. PubMed ID: 37487345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disease modifying therapies continue to drive up health care cost among individuals with multiple sclerosis.
    Kim Y; Krause TM; Blum P; Freeman L
    Mult Scler Relat Disord; 2019 May; 30():69-75. PubMed ID: 30738875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data.
    Engmann NJ; Sheinson D; Bawa K; Ng CD; Pardo G
    J Manag Care Spec Pharm; 2021 May; 27(5):639-649. PubMed ID: 33624535
    [No Abstract]   [Full Text] [Related]  

  • 17. The economic burden of psoriasis with high comorbidity among privately insured patients in the United States.
    Pilon D; Teeple A; Zhdanava M; Ladouceur M; Ching Cheung H; Muser E; Lefebvre P
    J Med Econ; 2019 Feb; 22(2):196-203. PubMed ID: 30523738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One-Year Outcomes of an Integrated Multiple Sclerosis Disease Management Program.
    Groeneweg M; Forrester SH; Arnold B; Palazzo L; Zhu W; Yoon P; Scearce T
    J Manag Care Spec Pharm; 2018 May; 24(5):458-463. PubMed ID: 29694287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct and indirect costs associated with Dupuytren's contracture.
    Macaulay D; Ivanova J; Birnbaum H; Sorg R; Skodny P
    J Med Econ; 2012; 15(4):664-71. PubMed ID: 22369346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost, healthcare resource utilization, and adherence of individuals with diabetes using U-500 or U-100 insulin: a retrospective database analysis.
    Eby EL; Wang P; Curtis BH; Xie J; Haldane DC; Idris I; Peters AL; Hood RC; Jackson JA
    J Med Econ; 2013; 16(4):529-38. PubMed ID: 23363330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.